Skip to main content
SpringerLink
Log in

Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy

  • Brief Report
  • Published:
Cell Biology and Toxicology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  • Barschak AG, Sitta A, Deon M, et al. Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metab Brain Dis. 2006;21(4):279–86.

    Article  CAS  PubMed  Google Scholar 

  • Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78(2):547–81.

    CAS  PubMed  Google Scholar 

  • Berry HK. Screening for mucopolysaccharide disorders with the Berry spot test. Clin Biochem. 1987;20:365–71.

    Article  CAS  PubMed  Google Scholar 

  • Biancini GB, Vanzin CS, Rodrigues DB, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012;1822:226–32.

    Article  CAS  PubMed  Google Scholar 

  • Blau N, Duran M, Blaskovics ME, et al. Approach to diagnosis. Simple tests in urine and blood. In: Blau N et al., editors. Physician’s guide to the laboratory diagnosis of metabolic diseases. New York: Chapman & Hall Medical; 1996. p. 3–12.

  • Coelho JC, Wajner M, Burin MG, et al. Selective screening of 10000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur J Pediatr. 1997;156:650–4.

    Article  CAS  PubMed  Google Scholar 

  • Deganuto M, Pittis MG, Pines A, et al. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol. 2007;212(1):223–35.

    Article  CAS  PubMed  Google Scholar 

  • Di Domenico C, Villani GR, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A. 2009;149A(6):1209–18.

    Article  PubMed  Google Scholar 

  • Esterbauer, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407–21.

    Article  CAS  PubMed  Google Scholar 

  • Germain DP. Enzyme replacement therapies for lysosomal storage disorders. Med Sci. 2005;21(11):77–83.

    Google Scholar 

  • Giugliani R, Rojas VM, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2009;96(1):13–9.

    Article  CAS  PubMed  Google Scholar 

  • Halliwell B, Gutteridge JMC, editors. Free radicals in biology and medicine. Oxford: Oxford University Press; 2007.

    Google Scholar 

  • Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94(4):469–75.

    Article  CAS  PubMed  Google Scholar 

  • Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem. 1992;38(6):803–7.

    PubMed  Google Scholar 

  • Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme replacement therapy in mucopolysaccharidosis I. N Eng J Med. 2001;344:182–8.

    Article  CAS  Google Scholar 

  • Mabe P, Valiente A, Soto V, et al. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta. 2004;345:135–40.

    Article  CAS  PubMed  Google Scholar 

  • Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–37.

    Article  CAS  PubMed  Google Scholar 

  • Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw Hill; 2001.

    Google Scholar 

  • Pereira VG, Martins AM, Micheletti C, D’Almeida V. Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clin Chim Acta. 2008;387(1–2):75–9.

    Article  CAS  PubMed  Google Scholar 

  • Ribas GS, Pires R, Coelho JC, et al. Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int J Dev Neurosci. 2012;30(6):439–44.

    Article  CAS  PubMed  Google Scholar 

  • Roversi FM, Galdieri LC, Grego BHC, Souza FG, Micheletti C, Martins AM, et al. Blood oxidative stress markers in Gaucher disease patients. Clin Chim Acta. 2006;364(1–2):316–20.

    Article  CAS  PubMed  Google Scholar 

  • Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184–91.

    Article  CAS  PubMed  Google Scholar 

  • Sitta A, Barschak AG, Deon M, et al. Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis. 2006;21(4):287–96.

    Article  CAS  PubMed  Google Scholar 

  • Vargas CR, Wajner M, Sirtori LR, et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodistrophy. Biochim Biophys Acta. 2004;1688(1):26–32.

    Article  CAS  PubMed  Google Scholar 

  • Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis. 2001;24(6):675–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundo de Incentivo à Pesquisa e Eventos (FIPE/HCPA). We also thank the patients who participated in this study for all the support during the research.

Conflict of interest

All authors declare that there are no financial or commercial conflicts of interest.

Author information

Authors and Affiliations

  1. Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, 1° andar, Porto Alegre, RS, 90610-000, Brazil

    G. W. Negretto & C. R. Vargas

  2. Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre (HCPA), Ramiro Barcelos 2350, Porto Alegre, RS, 90035-903, Brazil

    G. W. Negretto, M. Deon, G. B. Biancini, M. G. Burin, R. Giugliani & C. R. Vargas

Authors
  1. G. W. Negretto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Deon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. B. Biancini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. G. Burin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Giugliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. R. Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to G. W. Negretto or C. R. Vargas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Negretto, G.W., Deon, M., Biancini, G.B. et al. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy. Cell Biol Toxicol 30, 189–193 (2014). https://doi.org/10.1007/s10565-014-9284-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10565-014-9284-3

Keywords

Search

Navigation